Co.don

Co.don FCF per Share

Delisted

The Free Cash Flow per Share of Co.don (CNWK.DE) as of Nov 10, 2026 is -0.31 EUR. In the previous year, Free Cash Flow per Share was -0.61 EUR — a change of -48.38% (higher).

FCF per Share

-0.31EUR

YoY

-48.38%

Last updated:

Free Cash Flow per Share of Co.don is 2020 -0.31 EUR. Free Cash Flow per Share of Co.don was 2019 -0.61 EUR. It decreases by -48.38% higher compared to the previous year.

The Co.don FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2014
-0.16 EUR
Jan 1, 2015
-0.25 EUR
Jan 1, 2016
-0.22 EUR
Jan 1, 2017
-0.47 EUR
Jan 1, 2018
-0.73 EUR
Jan 1, 2019
-0.61 EUR
Jan 1, 2020
-0.31 EUR
The Co.don FCF per Share history
YEARFCF per ShareYoY
-0.31EUR-48.38%
-0.61EUR-17.26%
-0.73EUR+57.27%
-0.47EUR+113.19%
-0.22EUR-11.56%
-0.25EUR+59.56%
-0.16EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co.don Stock analysis

What does Co.don do? Co.don AG is a German company specializing in regenerative medicine. The company was founded in 1993 and is headquartered in Teltow near Berlin. Co.don aims to develop innovative therapies for tissue and joint damage to enable faster recovery for patients. Co.don's business model is based on the concept of tissue engineering. The company produces autologous cell therapies based on a patient's own cells. This means that the patient's own tissue is harvested to cultivate new and healthy cells that can be implanted back into the patient's body. Co.don offers various divisions to best meet the needs of patients. One of the most well-known divisions is cartilage cell therapy, which was developed to provide patients with the opportunity to heal damaged cartilage tissue in a gentle and effective manner. Another area in which the company operates is bone cell therapy. Autologous bone cells are produced to regenerate fractured or diseased bones. The company also has a division for skin-based cell therapy, which aims to heal tissue defects and minimize scarring. Co.don also offers various products tailored to the specific needs of patients. One of the most well-known products is the "Co.don Chondrosphere®" implant, made from autologous cartilage cell tissue. This implant is used to repair cartilage damage in joints and other areas of the body. Another product offered by the company is the "Co.don ViviSpray®" bone substitute material. It is produced by mixing autologous bone cells with a carrier material to promote natural bone formation. In recent years, the company has gained increasing international recognition and is now a well-known player in the field of regenerative medicine. The company has received numerous awards and has conducted several successful clinical trials that demonstrate the effectiveness of Co.don's products. Overall, Co.don AG is a company specializing in the production of autologous cell therapies. The company offers various divisions and manufactures products tailored to the specific needs of patients. With its innovative work, Co.don has contributed to revolutionizing the way tissue and joint damage are treated. Co.don is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co.don stock

Free Cash Flow per Share of Co.don is -0.31 EUR in 2020.

Free Cash Flow per Share of Co.don changed from -0.61 EUR to -0.31 EUR, representing a -48.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Co.don since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Co.don

All Key Metrics — Co.don